Zorgstandaard Neurofibromatose type-2

92 / 106

92
[58]H. S. Lim, J. Jung, and K. Y. Chung, “Neurofibromatosis type 2 with multiple plexiform schwannomas,”
Int. J. Dermatol., vol. 43, no. 5, pp. 336–340, 2004.
[59] J. L. Rodríguez-Peralto, E. Riveiro-Falkenbach, and R. Carrillo, “Benign cutaneous neural tumors,” Semin.
Diagn. Pathol., vol. 30, no. 1, pp. 45–57, Feb. 2013.
[60] C. M. Patel, R. Ferner, and E. A. Grunfeld, “A qualitative study of the impact of living with
neurofibromatosis type 2,” Psychol Health Med, vol. 16, no. 1, pp. 19–28.
[61]N. Guinand, F. Boselie, J.-P. Guyot, and H. Kingma, “Quality of life of patients with bilateral
vestibulopathy,” Ann. Otol. Rhinol. Laryngol., vol. 121, no. 7, pp. 471–477, Jul. 2012.
[62] S. Kim, Y.-M. Oh, J.-W. Koo, and J. S. Kim, “Bilateral vestibulopathy: clinical characteristics and diagnostic
criteria,” Otol. Neurotol. Off. Publ. Am. Otol. Soc. Am. Neurotol. Soc. Eur. Acad. Otol. Neurotol., vol. 32,
no. 5, pp. 812–817, Jul. 2011.
[63] J. C. Jen, “Bilateral vestibulopathy: clinical, diagnostic, and genetic considerations,” Semin. Neurol., vol.
29, no. 5, pp. 528–533, Nov. 2009.
[64]W. P. Godefroy, D. Hastan, and A. G. L. van der Mey, “Translabyrinthine surgery for disabling vertigo in
vestibular schwannoma patients,” Clin. Otolaryngol. Off. J. ENT-UK Off. J. Neth. Soc. Oto-Rhino-Laryngol.
Cervico-Facial Surg., vol. 32, no. 3, pp. 167–172, Jun. 2007.
[65]N. Rumsey and D. Harcourt, “Body image and disfigurement: issues and interventions,” Body Image, vol.
1, no. 1, pp. 83–97, Jan. 2004.
[66]H. Breivik, B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher, “Survey of chronic pain in Europe:
prevalence, impact on daily life, and treatment,” Eur. J. Pain Lond. Engl., vol. 10, no. 4, pp. 287–333, May
2006.
[67]D. C. Turk and E.S. Monarch, “Biopsychosocial Perspective on Chronic Pain,” in Psychological Approaches
to Pain Management: A Practitioner’s Handbook, D.C. Turk and R.J. Gatchel., Guilford Press, 2002, pp. 3–
29.
[68] Emma Kinderziekenhuis and AMC, “Omvang en gevolgen van chronische aandoeningen bij kinderen,”
Sep. 2006.
[69] Van Breukelen, S., “Organisatie en concentratie van zorg bij zeldzame aandoeningen.” VSOP, 2013.
[70] “Integrale zorg voor chronisch zieken - Zorg voor chronisch zieken - .” [Online]. Available:
[Accessed: 14-
Feb-2014].
[71]H. W. Drewes, Boom, J.H.C., Graafmans, W.C., Struijs , J.N., and Baan , C.A., “Effectiviteit van disease
management. Een overzicht van de (internationale) literatuur,” RIVM, 260131001, 2008.
[72] KNMG, V&VN, KNOV, KNGF, KNMP, NIP, NVZ, NFU, GGZ Nederland, NPCF, “Handreiking
Verantwoordelijkheidsverdeling bij samenwerking in de zorg.” 26-Jan-2010.
[73] Besluit zorgplanbespreking AWBZ-zorg. 2009.
[74] Coördinatieplatform Zorgstandaarden, “Raamwerk individueel zorgplan.” maart-2012.
[75] E. H. Wagner, B. T. Austin, C. Davis, M. Hindmarsh, J. Schaefer, and A. Bonomi, “Improving chronic illness
care: translating evidence into action,” Health Aff. Proj. Hope, vol. 20, no. 6, pp. 64–78, Dec. 2001.
[76] R. W. Blum, D. Garell, C. H. Hodgman, T. W. Jorissen, N. A. Okinow, D. P. Orr, and G. B. Slap, “Transition
from child-centered to adult health-care systems for adolescents with chronic conditions. A position
paper of the Society for Adolescent Medicine,” J. Adolesc. Health Off. Publ. Soc. Adolesc. Med. , vol. 14,
no. 7, pp. 570–576, Nov. 1993.
[77] Royal College of Nursing, “Transitiezorg voor adolescenten. Richtlijn voor verpleeegkundigen,” Richtlijn,
2008.
[78]Ministerie van Veiligheid en Justitie, Burgerlijk Wetboek Boek 7. De overeenkomst inzake geneeskundige
behandeling. .
[79] Revalidatie Nederland, “Revalidatie Toekomstverkenning 2015,” Utrecht, Dec. 2006.
[80] Revalidatie Nederland, “Factsheet Kinderrevalidatie.” Apr-2010.